Genomics

Dataset Information

0

Data access committee handling data access requests for biomarker data from the clinical trial IMvigor210.


ABSTRACT: Data Access Committee EGAC00001000945

PROVIDER: EGAC00001000945 | EGA |

REPOSITORIES: EGA

altmetric image

Publications

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Mariathasan Sanjeev S   Turley Shannon J SJ   Nickles Dorothee D   Castiglioni Alessandra A   Yuen Kobe K   Wang Yulei Y   Kadel Edward E EE   Koeppen Hartmut H   Astarita Jillian L JL   Cubas Rafael R   Jhunjhunwala Suchit S   Banchereau Romain R   Yang Yagai Y   Guan Yinghui Y   Chalouni Cecile C   Ziai James J   Şenbabaoğlu Yasin Y   Santoro Stephen S   Sheinson Daniel D   Hung Jeffrey J   Giltnane Jennifer M JM   Pierce Andrew A AA   Mesh Kathryn K   Lianoglou Steve S   Riegler Johannes J   Carano Richard A D RAD   Eriksson Pontus P   Höglund Mattias M   Somarriba Loan L   Halligan Daniel L DL   van der Heijden Michiel S MS   Loriot Yohann Y   Rosenberg Jonathan E JE   Fong Lawrence L   Mellman Ira I   Chen Daniel S DS   Green Marjorie M   Derleth Christina C   Fine Gregg D GD   Hegde Priti S PS   Bourgon Richard R   Powles Thomas T  

Nature 20180214 7693


Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer. However, these responses only occur in a subset of patients. Elucidating the determinants of response and resistance is key to improving outcomes and developing new treatment strategies. Here we examined tumours from a large cohort of patients with metastatic urothelial cancer wh  ...[more]

Similar Datasets

| EGAC00001000946 | EGA
| EGAC00001002826 | EGA
| EGAC00001001084 | EGA
| EGAC00001003341 | EGA
| EGAC00001001901 | EGA
| EGAC00001002863 | EGA
| EGAC00001002333 | EGA
| PRJNA625583 | ENA
| PRJNA625584 | ENA
| S-EPMC3617375 | biostudies-literature